Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
9.92
-0.87 (-8.06%)
Mar 31, 2025, 1:27 PM EDT - Market open
Keros Therapeutics Employees
Keros Therapeutics had 169 employees as of December 31, 2024. The number of employees increased by 33 or 24.26% compared to the previous year.
Employees
169
Change (1Y)
33
Growth (1Y)
24.26%
Revenue / Employee
$21,006
Profits / Employee
-$1,108,598
Market Cap
402.38M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
KROS News
- 4 weeks ago - Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - GlobeNewsWire
- 4 weeks ago - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 2 months ago - Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 2 months ago - Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation - Accesswire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect - Accesswire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation - Accesswire